Treatment and treatment trials in multiple sclerosis

Bernd C. Kieseier, Heinz Wiendl, Bernhard Hemmer, Hans Peter Hartung

Research output: Contribution to journalReview articlepeer-review

50 Scopus citations


PURPOSE OF REVIEW: This review focuses on advances in current and novel treatment approaches in multiple sclerosis. RECENT FINDINGS: New therapeutic approaches in multiple sclerosis are emerging. Orally available treatment strategies are more acceptable for patients and may improve adherence to therapy. An oral formulation of glatiramer acetate failed to demonstrate efficacy in a clinical trial, but other promising compounds are on the horizon, such as FTY720. Advances are currently being made in use of therapeutic monoclonal antibodies that specifically target key molecules involved in the immunopathogenesis of multiple sclerosis. Natalizumab directed against the adhesion molecule very late antigen-4 represents the first specific antibody to be added to our therapeutic armamentarium for multiple sclerosis. Further evidence that immunomodulation should be initiated as early as possible has been reported. SUMMARY: Treatment of multiple sclerosis has changed dramatically over the past decade. Enhanced understanding of the immunopathological processes that underlie the disease, advances in biotechnology and development of powerful magnetic resonance imaging technologies, together with improvements in clinical trial design have led to a variety of valuable therapeutic approaches, which are currently being studied in detail.

Original languageEnglish
Pages (from-to)286-293
Number of pages8
JournalCurrent Opinion in Neurology
Issue number3
StatePublished - Jun 2007
Externally publishedYes


  • CC chemokine receptor 1
  • Clinically isolated syndrome
  • Daclizumab
  • Early treament
  • FTY720
  • Glatiramer acetate
  • Interferon beta
  • Intravenous immunoglobulins
  • Natalizumab
  • Rituximab


Dive into the research topics of 'Treatment and treatment trials in multiple sclerosis'. Together they form a unique fingerprint.

Cite this